GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Valuation Rank

Glaukos (FRA:6GJ) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Glaukos Valuation Rank Related Terms

Thank you for viewing the detailed overview of Glaukos's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Valuation Rank
Comparable Companies
BRKR INSP BIO ITGR IRTC PRCT HAE MASI QDEL TMDX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
GKOS:USA 6GJ:Germany
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Website
https://www.glaukos.com
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.